Skip to main content
. Author manuscript; available in PMC: 2012 Oct 13.
Published in final edited form as: Vaccine. 2011 Aug 12;29(44):7631–7637. doi: 10.1016/j.vaccine.2011.08.009

Fig. 5.

Fig. 5

ELISA quantitation of soluble (s) and fibrillar (f) cerebral amyloid (Aß40/42) in 5XFAD brain after intranasal delivery of anti-Aß antibody with and without WGA conjugation. Data are represented as (ng)/mg Protein) {Mean ± standard deviation (SD)}. Note that anti-Aß antibody with WGA conjugation showed prominent reduction of soluble, but not fibrillar, Aß species in 5XFAD brain.